
Home > About Takeda > History > 2000-
Main contents starts here
Utilizing Celera's genomic information, Takeda has been facilitating our discovery research on orphan receptors and ligands and to discover unknown enzyme genes and disease-related genes.
In order to concentrate management resources into pharmaceutical businesses, Takeda has been restructuring animal health business, bulk vitamin business, urethane chemicals business, food business, agro business and life-environment business our non-pharmaceutical businesses as originally planned in the 2001-2005 Medium-Term Management Plan.
and its 100% owned subsidiaries (one in Austria "" and the other in Switzerland "") became a 100% subsidiary of Takeda Europe Holdings Ltd.

Takeda Pharma Ireland Limited
It is our first bulk pharmaceutical manufacturing site outside Japan. Takeda aims to minimize costs by establishing manufacturing operations in convenient locations worldwide.
Takeda has integrated the development function in the U.S., Europe and Japan. By reinforcing the development system and its function at a global level, Takeda aims to accelerate the progress of development stages of our products and to achieve its early launch onto the market in the tri-polar markets.
The company changed its name to

Rozerem
Takeda Pharmaceuticals Europe Limited leads operations in Europe and accelerates pan-European strategies for the medium to long term.

New home office of Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
The opening of the new home offices in the United States is one of the greatest achievements for establishing and enhancing Takeda's U.S. business.
Takeda now has research functions in Japan, the U.S., Europe, and in Singapore. This acquisition surely represents our initiatives for establishing global research infrastructures and for pursuing the world's highest standard of productivity.
The company and its subsidiary renamed and Takeda Singapore Pte Limited.